Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 2/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.49 |
| ▸ | LTK | P29376 | 1/20 | 0.49 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.49 |
| ▸ | CDK8 | P49336 | 1/20 | 0.49 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.49 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.47 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2480174 | 0.84 | ADORA1 (0.49) | MAPK8CHEK1DAPK3LTKCSNK1A1 | |
| SCHEMBL2480149 | 0.81 | BCHE (0.46) | ADORA1KDM4ENPC1MAPTTSHR | |
| SCHEMBL7497588 | 0.77 | ACHE (0.43) | ADORA1TP53MAPTACHESRD5A2 | |
| SCHEMBL2477067 | 0.74 | KDM4E (0.53) | KDM4EMEN1NPC1MAPTPKM | |
| SCHEMBL2477193 | 0.71 | KDR (0.40) | MEN1TP53CYP2D6MAPTKMT2A | |
| SCHEMBL29816885 | 0.68 | MAPK8 (0.50) | MAPK8CHEK1DAPK3LTKCSNK1A1 | |
| SCHEMBL2439631 | 0.68 | MAPK8 (0.50) | MAPK8CHEK1DAPK3LTKCSNK1A1 | |
| SCHEMBL4959991 | 0.66 | CHEK1 (1.00) | MAPK8CHEK1DAPK3LTKCSNK1A1 | |
| SCHEMBL31321386 | 0.66 | CHEK1 (1.00) | MAPK8CHEK1DAPK3LTKCSNK1A1 | |
| SCHEMBL12798139 | 0.66 | CHEK1 (0.65) | MAPK8CHEK1DAPK3LTKCSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3386511-B1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2021-05-12 | — | — | EP | claimed |
| US-10874672-B2 | Methods for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | claimed |
| US-8349857-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-01-08 | — | — | US | claimed |
| EP-1441719-B1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-03-30 | — | — | EP | claimed |
| US-7803819-B2 | DPP IV inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2010-09-28 | — | — | US | claimed |
| US-20070259925-A1 | DPP IV INHIBITORS | BOEHRINGER MARKUS | 2007-11-08 | — | — | US | claimed |
| US-20050096348-A1 | DPP IV inhibitors | BOEHRINGER MARKUS (CH) | 2005-05-05 | — | — | US | claimed |
| EP-1441719-A1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-04 | — | — | EP | claimed |
| US-20030130281-A1 | DPP IV inhibitors | HOFFMAN-LA ROCHE INC. | 2003-07-10 | — | — | US | claimed |
| WO-2003037327-A1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | F. HOFFMANN-LA-ROCHE AG (CH) | 2003-05-08 | — | — | WO | claimed |
| WO-2024115733-A1 | FUSED PYRROLYL-SULFONAMIDE COMPOUNDS | REWIND THERAPEUTICS NV (BE) | 2024-06-06 | — | — | WO | disclosed |
| EP-4347558-A1 | 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS | ReWind Therapeutics NV (BE) | 2024-04-10 | — | — | EP | disclosed |
| CN-117794898-A | 3-pyrrolylsulfonamide compounds as GPR17 antagonists | 瑞文德医疗公众有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2024059119-A2 | COMPOUNDS AND THEIR USE IN FILTERING ULTRAVIOLET AND/OR HIGH-ENERGY VISIBLE LIGHT | SOLIOME, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-3386511-B2 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20030195231-A1 | Compounds exhibiting thrombopoietin receptor agonism | SHIONOGI & CO., LTD. (JP) | 2003-10-16 | — | — | US | disclosed |
| US-20030130281-A1 | DPP IV inhibitors | HOFFMAN-LA ROCHE INC. | 2003-07-10 | — | — | US | disclosed |
| WO-2003037327-A1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | F. HOFFMANN-LA-ROCHE AG (CH) | 2003-05-08 | — | — | WO | disclosed |
| EP-1264820-A1 | NOVEL AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-11 | — | — | EP | disclosed |
| EP-1253142-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO., LTD. (JP) | 2002-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195231-A1 | Compounds exhibiting thrombopoietin receptor agonism | MPL, TEK, NPY1R | MAPK8 1087/4885CHEK1 2720/4885DAPK3 2414/4885 |
| US-10874672-B2 | Methods for treating Huntington's disease | HTT, HYPK, FH | MAPK8 4436/4885CHEK1 4380/4885DAPK3 3655/4885 |
| US-20070259925-A1 | DPP IV INHIBITORS | DPP4, DPP3, DPP7 | MAPK8 3464/4885CHEK1 4574/4885DAPK3 1417/4885 |
| US-20030130281-A1 | DPP IV inhibitors | DPP4, DPP3, DPP7 | MAPK8 3381/4885CHEK1 4652/4885DAPK3 1389/4885 |
| US-20050096348-A1 | DPP IV inhibitors | DPP4, DPP3, DPP7 | MAPK8 3464/4885CHEK1 4574/4885DAPK3 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.